Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Decline in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 500 shares, a decrease of 97.2% from the January 15th total of 18,000 shares. Based on an average daily volume of 485,900 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Price Performance

Shares of PVCT traded up $0.00 during mid-day trading on Wednesday, hitting $0.10. The company had a trading volume of 146,001 shares, compared to its average volume of 211,239. The business’s 50-day simple moving average is $0.12 and its 200-day simple moving average is $0.11. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.